128 results
Page 2 of 7
6-K
EX-99.2
a36d1cuvj n49mknlw1
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.1
mgnvdm412yhgey c6h
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.2
fi9docrvw7vcx69lym
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.1
vuh9zb y5ol
28 Jul 22
Current report (foreign)
2:52pm
6-K
EX-99
av2z4
26 Jul 22
Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
1:45pm
6-K
EX-99.4
38h4hktuii lcmr
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
1am i7mxjh3
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
nap58webrqciru45
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.3
596v07hdxpw5d8
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.1
t94es08639
29 Mar 22
RepliCel Announces Non-brokered Private Placement
1:02pm
6-K
EX-99.1
l2vzh5h0
29 Mar 22
RepliCel Announces Material Patent Milestones
12:51pm
6-K
EX-99.2
q4vobzqvqhtzuk9bb6a2
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
va3o8
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.1
iy6r2tz3oxv3u
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.1
dy2hs ysgydm0ivtfcl4
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
EX-99.1
f9c rlck0
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
EX-99.2
i8d 8v4mqby5c5
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
vfynewk 4yfxez1c2yp
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm
6-K
EX-99.4
7c5frh8cctfzhli8j8q6
18 Aug 21
Current report (foreign)
12:20pm